Why should we still care about oncogenes?

Molecular Cancer Therapeutics

Volumn 6, Issue 2, 2007, Pages 418-427

  Diehl, Kathleen M ^a   Keller, Evan T ^a   Woods Ignatoski, Kathleen M ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3,5 DI TERT BUTYL 4 HYDROXYPHENYL) 1,1 ETHANEBISPHOSPHONIC ACID TETRAISOPROPYL ESTER; ABELSON KINASE; ADAPTOR PROTEIN; ALANOSINE; AMONAFIDE; ANTINEOPLASTIC AGENT; BROSTALLICIN; CETUXIMAB; CLOFARABINE; DEHYDRODIDEMNIN B; DIFLOMOTECAN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; IMATINIB; INFLIXIMAB; MATUZUMAB; MITOGEN ACTIVATED PROTEIN KINASE; NEW DRUG; PANITUMUMAB; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE; PX 12; SUNITINIB; TESMILIFENE; TRASTUZUMAB; TROXACITABINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

CANCER GROWTH; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG RESPONSE; DRUG TARGETING; ENZYME ACTIVITY; GENE ACTIVITY; HUMAN; MALIGNANT TRANSFORMATION; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTO ONCOGENE; REVIEW;

ANIMALS; HUMANS; NEOPLASMS; ONCOGENES;

EID: 33847398765     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0603     Document Type: Review

References (112)

1. Rous P. A sarcoma of fowl transmissible by an agent separable from the tumor cells. J Exp Med 7911;13:397-411.
2. Duesberg PH, Vogt PK. Differences between the ribonucleic acids of transforming and nontransforming avian tumor viruses. Proc Natl Acad Sci U S A 1970;67:1673-80.
3. Stehelin D, Varmus HE, Bishop JM, Vogt PK. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature 1976;260:170-3.
4. Shih C, Padhy LC, Murray M, Weinberg RA. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 1981;290:261-4.
5. Toyoshima K, Akiyama T, Mori S, et al. Structure and function of the erbB gene family. IARC Sci Publ 1988;92:149-58.
6. McCormick F. Ras-related proteins in signal transduction and growth control. Mol Reprod Dev 1995;42:500-6.
7. Parsons JT, Weber MJ. Genetics of src: structure and functional organization of a protein tyrosine kinase. Curr Top Microbiol Immunol 1989;147:79-127.
8. Mayer BJ, Hamaguchi M, Hanafusa H. Characterization of p47gag-crk, a novel oncogene product with sequence similarity to a putative modulatory domain of protein-tyrosine kinases and phospholipase C. Cold Spring Harb Symp Quant Biol 1988;53:907-14.
9. Sheiness D, Bishop JM. DNA and RNA from uninfected vertebrate cells contain nucleotide sequences related to the putative transforming gene of avian myelocytomatosis virus. J Virol 1979;31:514-21.
10. Hanks S, Hunter T. The protein kinase facts book. 1st ad. San Diego (CA): Academic Press, Inc.; 1995.
11. Lin CR, Chen WS, Kruiger W, et al. Expression cloning of human EGF receptor complementary DNA: gene amplification and three related messenger RNA products in A431 cells. Science 1984;224:843-8.
12. Simmen FA, Gope ML, Schulz TZ, et al. Isolation of an evolutionarily conserved epidermal growth factor receptor cDNA from human A431 carcinoma cells. Biochem Biophys Res Commun 1984;124:125-32.
13. Downward J, Yarden Y, Mayes E, et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 1984;307:521-7.
14. Carpenter G. Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem 1987;56:881-914.
15. McKenzie SJ. Diagnostic utility of oncogenes and their products in human cancer. Biochim Biophys Acta 1991;1072:193-214.
16. Gusterson B. Identification and interpretation of epidermal growth factor and c-erbB-2 overexpression. Eur J Cancer 1992;28:263-7.
17. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
18. Nicholson S, Wright C, Sainsbury JR, et al. Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: neu and tamoxifen failure #1738. J Steroid Biochem Mol Biol 1990;37:811-4.
19. Jost M, Huggett TM, Kari C, Boise LH, Rodeck U. Epidermal growth factor receptor-dependent control of keratinocyte survival and Bcl-xL expression through a MEK-dependent pathway. J Biol Chem 2001;276: 6320-6.
20. Wang X, McCullough KD, Franke TF, Holbrook NJ. Epidermal growth factor receptor-dependent Akt activation by oxidative stress enhances cell survival. J Biol Chem 2000;275:14624-31.
21. Campiglio M, Locatelli A, Olgiati C, et al. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (Iressa) is independent of EGFR expression level. J Cell Physiol 2004;198:259-68.
22. Reginato MJ, Mills KR, Paulus JK, et al. Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat Cell Biol 2003;5:733-40.
23. Woods Ignatoski KM, Dziubinski ML, Ammerman CA, Ethier SP. Cooperative interactions of HER-2 and HPV-16 oncoproteins in the malignant transformation of human mammary epithelial cells. Neoplasia 2005;7:788-98.
24. Lonardo F, DiMarco E, King CR, et al. The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand. New Biol 1990;2:992-1003.
25. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
26. Chan R, Muller WJ, Siegel PM. Oncogenic activating mutations in the neu/ erbB-2 oncogene are involved in the induction of mammary tumors. Ann N Y Aced Sci 1999;889:45-51.
27. Bergmann CI, Hung MC, Weinberg RA. Multiple independent activations of the c-neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 1986;45:649-57.
28. Kraus M, Popescu N, Amsbaugh S, King C. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J 1987;6:605-10.
29. Lacroix H, Iglehart JD, Skinner MA, Kraus MH. Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases #147. Oncogene 1989;4:145-51.
30. Guerin M, Gabillot M, Mathieu MC, et al. Structure and expression of c-erbB-2 and EGF receptor genes inflammatory and non-inflammatory breast cancer: prognostic significance. Int J Cancer 1989;43:201-8.
31. Woods Ignatoski KM, LaPointe AJ, Radany EH, Ethier SP. ErbB-2 overexpression in human mammary epithelial cells confers growth factor independence. Endocrinology 1999;140:3615-22.
32. Woods Ignatoski KM, Maehama T, Markwart SM, et al. ERBB-2 overexpression confers PI 3'-kinase-dependent invasion capacity on human mammary epithelial cells. Br J Cancer 2000;82:666-74.
33. Woods Ignatoski KM. Immunoprecipitation and Western blotting of phosphotyrosine-containing proteins. In: Reith A, editor. Protein kinase protocols. Totowa (NJ): Humana Press, Inc.; 2001. p. 39-48.
34. She QB, Solit DB, Ye Q, et al. The BAD protein integrates survival signaling by EGFR/MAPK and P13K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 2005;8:287-97.
35. Slamon D, Leyland-Jones B, Shak S, et al. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: a randomized, multinational controlled phase III trial. #1806. Proc Am Soc Clin Oncol 1998;377:98a.
36. Mendelsohn J. Epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. J Natl Cancer Inst Monogr 1992;13:125-31.
37. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737-44.
38. Medrano EE, Resnicoff M, Cafferata EGA, et al. Increased secretory activity and estradiol receptor expression are among other relevant aspects of MCF-7 human breast tumor cell growth which are expressed only in the absence of serum #309. Exp Cell Res 1990;188:2-9.
39. Normanno N, Maiello M, De Luca A. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action? J Cell Physiol 2003;194:13-9.
40. Normanno N, Bianco C, De Luca A, Maiello M, Salomon D. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 2003;10:1-21.
41. Dancey J. Epidermal growth factor receptor inhibitors in clinical development. Int J Radiat Oncol Biol Phys 2004;58:1003-7.
42. Mayer BJ, Jackson PK, Baltimore D. The noncatalytic src homology region 2 segment of abl tyrosine kinase binds to tyrosine-phosphorylated cellular proteins with high affinity. Proc Natl Acad Sci U S A 1991;88: 627-31.
43. Ren R, Mayer BJ, Cicchetti P, Baltimore D. Identification of a ten-amino acid proline-rich SH3 binding site. Science 1993;259:1157-61.
44. Lowenstein EJ, Daly RJ, Batzer AG, et al. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to Ras signaling #688. Cell 1992;70:431-42.
45. Li N, Batzer A, Daly R, et al. Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling. Nature 1993;363:85-8.
46. Casey P. Lipid modifications of G proteins. Curr Opin Cell Biol 1994;6: 219-25.
47. Cobb M, Xu S, Hepler J, et al. Regulation of the MAP kinase cascade. Cell Mol Biol Res 1994;40:253-6.
48. Williams N, Roberts T. Signal transduction pathways involving the Raf proto-oncogene. Cancer Metastasis Rev 1994;13:105-16.
49. Guan K. The mitogen activated protein kinase signal transduction pathway: from the cell surface to the nucleus. Cell Signal 1994;6:581-9.
50. Perrimon N. Signalling pathways initiated by receptor protein tyrosine kinases in Drosophila. Curr Opin Cell Biol 1994;2:260-6.
51. Downward J. Control of ras activation. Cancer Surv 1996;27:87-100.
52. Duncia J, Santella JB III, Higley C, et al. MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products. Bioorg Med Chem Lett 1998;8:2839-44.
53. Alessi D, Cuenda A, Cohen P, Dudley D, Saltiel A. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995;270:27489-94.
54. Allen L, Sebolt-Leopold J, Meyer M. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol 2003;30: 105-16.
55. Lyons JF, Wilhelm S, Hibner B, Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001;8:219-25.
56. Hotte S, Hirte H. BAY 43-9006: early clinical data in patients with advanced solid malignancies. Curr Pharm Des 2002;8:2249-53.
57. Gunasekaran K, Tsai C-J, Kumar S, Zanuy D, Nussinov R. Extended disordered proteins: targeting function with less scaffold. Trends Biochem Sci 2003;28:81-5.
58. Venet M, End D, Angibaud P. Farnesyl protein transferase inhibitor ZARNESTRA R115777 to history of a discovery. Curr Top Med Chem 2003;3:1095-102.
59. Santucci R, Mackley P, Sebti S. Farnesyltransferase inhibitors and their role in the treatment of multiple myeloma. Cancer Control 2003;10:384-7.
60. Dempke WC. Farnesyltransferase inhibitors - a novel approach in the treatment of advanced pancreatic carcinomas. Anticancer Res 2003;23: 813-8.
61. Auger KR, Serunian LA, Soltoff SP, Libby P, Cantley LC. PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells. Cell 1989;57:167-75.
62. Jin W, Huang ESC, Bi WQ, Cote GJ. Exon sequence is required for regulated RNA splicing of the human fibroblast growth factor receptor-1 α-exon. J Biol Chem 1998;273:16170-6.
63. Novak U, Mui A, Miyajima A, Paradiso L. Formation of STAT5-containing DNA binding complexes in response to colony-stimulating factor-1 and platelet-derived growth factor. J Biol Chem 1996;271: 18350-4.
64. Burgering BMT, Coffer PJ. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 1995;376:599-602.
65. Cheatham B, Vlahos CJ, Cheatham L, et al. Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70 S6 kinase, DNA synthesis, and glucose transporter translocation. Mol Cell Biol 1994;14: 4902-11.
66. Datta K, Bellacosa A, Chan TO, Tsichlis PN. Akt is a direct target of the phosphatidylinositol 3-kinase. J Biol Chem 1996;271:30835-9.
67. Kolanus W, Seed B. Integrins and inside-out signal transduction: converging signals from PKC and PIP3. Curr Opin Cell Biol 1997;9:725-31.
68. Cockcroft S. Mammalian phosphotidylinositol transfer proteins: emerging roles in signal transduction and vesicular traffic. Chem Phys Lipids 1999;98:23-33.
69. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91: 231-41.
70. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998;273:13375-8.
71. Tamura M, Gu J, Takino T, Yamada KM. Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas. Cancer Res 1999;59:442-9.
72. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002;14:381-95.
73. Natarajan V, Vepa S, al-Hassani M, Scribner W. The enhancement by wortmannin of protein kinase C-dependent activation of phospholipase D in vascular endothelial cells. Chem Phys Lipids 1997;86:65-74.
74. Hay N, Sonenburg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926-45.
75. Bjornsti M, Houghton P. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004;12:335-48.
76. Granville C, Memmott R, Gills J, Dennis P. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res 2006;12:679-89.
77. Mathushansky I, Maki R. Mechanisms of sarcomagenesis. Hematol Oncol Clin North Am 2005;19:427-49.
78. Hennesey B, Smith D, Ram P, Lu Y, Mills G. Exploiting the P13K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005;4:988-1004.
79. Castedo M, Ferri K, Kroemer G. Mammalian target of rapamycin (mTOR): pro- and anti-apoptotic. Cell Death Differ 2002;9:99-100.
80. Vignot S, Faivre S, Aquirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005;16:525-37.
81. Morgenstern D, McCloud H. P13K/AKY/mTOR pathway as a target for cancer therapy. Anticancer Drugs 2005;16:797-803.
82. Beuvink I, Boulay A, Fumagalli S, et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damage induced apoptosis through inhibition of p21 translation. Cell 2005;120:747-59.
83. White S, Gharbi S, Bertani M, Chan H-L. Cellular responses to ErbB-2 overexpression in human mammary epithelial cells: comparison of mRNA and protein expression. Br J Cancer 2004;90:173-81.
84. Hosoi H, Dilling M, Liu L, et al. Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol Pharmacol 1998;54:815-24.
85. Dilling M, Germain G, Dudkin L, et al. 4E-binding proteins, the suppressors of eukayotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin. J Biol Chem 2002;277: 13907-17.
86. Hosoi H, Dilling M, Shikata T, et al. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res 1999;59:173-81.
87. Nowell P, Hungerford D. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 1960;25:85-109.
88. Rowley J. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290-3.
89. Groffen J, Stephenson J, Heisterkamp N, et al. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984;36:93-9.
90. Lugo T, Pendergast A, Muller A, Witte O. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990;247: 1079-82.
91. Daley G, Van Etten R, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;247:824-30.
92. Heisterkamp N, Jenster G, ten Hoeve J, et al. Acute leukaemia in bcr/abl transgenic mice. Nature 1990;344:251-3.
93. Druker B, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
94. Mahon F, Deininger M, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor ST1571: diverse mechanisms of resistance. Blood 2000;96:1070-9.
95. Deininger M, Druker B. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 2003;55:401-23.
96. Druker B, Talpaz M, Resta D, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
97. Kantarjian H, Keating M, Estey E, et al. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-α and low-dose cytarabine. J Clin Oncol 1992;10: 772-8.
98. Kantarjian H, Keating M, Talpaz M, et al. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med 1987;83:445-54.
99. Kantarjian H, O'Brien S, Keating M, et al. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia 1997;11:1617-20.
100. Rummukainen JK, Salminen T, Lundin J, et al. Amplification of c-myc by fluorescence in situ hybridization in a population-based breast cancer tissue array. Mod Pathol 2001;14:1030-5.
101. George D. Targeting PDGF receptors in cancer-rationales and proof of concept clinical trials. Adv Exp Med Biol 2003;532:141-51.
102. Apperley J, Gardembas M, Melo J, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor β. N Engl J Med 2002;347:481-7.
103. Anand N, Murthy S, Amann G, et al. Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. Nat Genet 2002;31:301-5.
104. von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002;359: 487-91.
105. Shah N, Nicoll J, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117-25.
106. Corbin A, Buchdunger E, Pascal F, Druker B. Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. J Biol Chem 2002;277:32214-9.
107. Hollis GF, Mitchell KF, Battey J, et al. A variant translocation places the λ immunoglobulin genes 3' to the c-myc oncogene in Burkitt's lymphoma. Nature 1984;307:752-5.
108. Rabbitts TH, Baer R, Davis M, et al. The c-myc gene paradox in Burkitt's lymphoma chromosomal translocation. Curr Top Microbiol Immunol 1984;113:166-71.
109. Berquin IM, Dziubinski ML, Nolan GP, Ethier SP. A functional screen for genes inducing epidermal growth factor autonomy of human mammary epithelial cells confirms the role of amphiregulin. Oncogene 2001;20: 4019-28.
110. Research CfDEa. Improving public health through human drugs. CDER Report to the Nation 2001.
111. Talpaz M, Kantarjian H, Kurzrock R, Trujillo J, Gutterman J. Interferon-α produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med 1991;114:532-8.
112. Jonkers J, Berns A. Oncogene addiction: sometimes a temporary slavery. Cancer Cell 2004;6:535-8.